Results 21 to 30 of about 120,218 (287)
CTLA-4: From conflict to clinic [PDF]
The Journal of Experimental Medicine, 2007 CTLA-4 was first identified in 1991 as a second receptor for the T cell costimulation ligand B7. Uncertainties about its biological function plagued the early years after its discovery until 1995, when it was confirmed to be an inhibitor of T cell responses.
openaire +2 more sources
Regulatory Cells, Cytokine Pattern and Clinical Risk Factors for Asthma in Infants and Young Children with Recurrent Wheeze [PDF]
, 2009 Several risk factors for asthma have been identified in infants and young children with recurrent wheeze. However, published literature has reported contradictory findings regarding the underlying immunological mechanisms.
Arroz, MJ +7 more
core +1 more source
, 2019 ALPSOY, ERKAN/0000-0001-7049-0170; uzun, soner/0000-0001-7059-5474; gunasti topal, suhan/0000-0003-0467-5884;
Bacanli, Ali +6 more
openaire +2 more sources
A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Molecular Oncology, EarlyView.Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti +3 more
wiley +1 more source
CTLA-4: a negative regulator of autoimmune disease. [PDF]
, 1996 CTLA-4, a CD28 homologue expressed on activated T cells, binds with high affinity to the CD28 ligands, B7-1 (CD80) and B7-2 (CD86). This study was designed to examine the role of CTLA-4 in regulating autoimmune disease.
Bluestone, JA +4 more
core
MALT1 proteolytic activity suppresses autoimmunity in a T cell intrinsic manner [PDF]
, 2019 MALT1 is a central signaling component in innate and adaptive immunity by regulating NF-kappa B and other key signaling pathways in different cell types. Activities of MALT1 are mediated by its scaffold and protease functions.
Baens, Mathijs +7 more
core +2 more sources
Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung +17 more
wiley +1 more source
Local Delivery of CTLA-4 Blockade Inhibits Growth of Pancreatic Tumors [PDF]
, 2016 Immune checkpoint blockade has demonstrated great potential in activating antitumor immunity. Ipilimumab is a monoclonal antibody which targets cytotoxic T-lymphocyte antigen-4. CTLA-4 belongs to the CD28 class of receptors and is found on the surface of
Baltz, Jack
core +2 more sources
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
Immunoregulatory soluble CTLA-4 modifies effector T cell responses in systemic lupus erythematosus [PDF]
, 2016 Acknowledgments This work was supported by Arthritis Research UK (Grant no. 19282). We are grateful to Dr. Nick Fluck for his invaluable support in recruiting patients for the study, and Mrs.
Barker, Robert N. +6 more
core +3 more sources